基于代谢组学的困倦标志物用于风险预防与交通安全(ME-SMART):一项单中心、对照、随机、交叉试验
本研究为单中心、对照、随机、交叉临床试验,计划纳入24名参与者,随机分配至对照、睡眠限制和睡眠剥夺三个研究组,各组仅每晚睡眠时长不同。主要结局为口腔液体代谢谱变化,次要结局包括驾驶表现、精神运动警觉测试、注意力测试、主观困倦、脑电图变化及呼出气和手指汗液代谢物浓度等。研究旨在建立指示困倦及其行为后果的候选生物标志物面板。
要点
- 计划纳入24名参与者,随机交叉分配至对照、睡眠限制和睡眠剥夺三组,各组仅每晚睡眠时长不同。
- 主要结局为口腔液体代谢谱变化,次要结局包括驾驶表现、精神运动警觉测试、d2注意力测试、视觉注意力测试、主观困倦、脑电图变化、呼出气和手指汗液代谢物浓度等。
- 研究旨在建立指示困倦及其行为后果的候选生物标志物面板。
核心结论
- 本研究旨在建立指示困倦及其行为后果的候选生物标志物面板。
- 迄今尚无稳健且易于获取的困倦检测生物标志物。
研究设计与样本
- 单中心、对照、随机、交叉临床试验,计划纳入24名参与者,随机分配至对照、睡眠限制和睡眠剥夺三个研究组,各组仅每晚睡眠时长不同。
- 对照条件为16/8小时清醒/睡眠方案;睡眠限制和睡眠剥夺条件均累积8小时总睡眠 deficit,通过不同清醒/睡眠方案模拟真实生活场景。
关键数值与推荐
- 主要结局为口腔液体代谢谱变化;次要结局包括驾驶表现、精神运动警觉测试、d2注意力测试、视觉注意力测试、主观(情境)困倦、脑电图变化、困倦行为标志物、呼出气和手指汗液代谢物浓度变化及生物基质间代谢变化相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Too little sleep and the consequences thereof are a heavy burden in modern societies. In contrast to alcohol or illicit drug use, there are no quick roadside or workplace tests for objective biomarkers for sleepiness. We hypothesize that changes in physiological functions (such as sleep-wake regulation) are reflected in changes of endogenous metabolism and should therefore be detectable as a change in metabolic profiles. This study will allow for creating a reliable and objective panel of candidate biomarkers being indicative for sleepiness and its behavioral outcomes. METHODS: This is a monocentric, controlled, randomized, crossover, clinical study to detect potential biomarkers. Each of the anticipated 24 participants will be allocated in randomized order to each of the three study arms (control, sleep restriction, and sleep deprivation). These only differ in the amount of hours slept per night. In the control condition, participants will adhere to a 16/8 h wake/sleep regime. In both sleep restriction and sleep deprivation conditions, participants will accumulate a total sleep deficit of 8 h, achieved by different wake/sleep regimes that simulate real-life scenarios. The primary outcome is changes in the metabolic profile (i.e., metabolome) in oral fluid. Secondary outcome measures will include driving performance, psychomotor vigilance test, d2 Test of Attention, visual attention test, subjective (situational) sleepiness, electroencephalographic changes, behavioral markers of sleepiness, changes in metabolite concentrations in exhaled breath and finger sweat, and correlation of metabolic changes among biological matrices. DISCUSSION: This is the first trial of its kind that investigates complete metabolic profiles combined with performance monitoring in humans over a multi-day period involving different sleep-wake schedules. Hereby, we aim to establish a candidate biomarker panel being indicative for sleepiness and its behavioral outcomes. To date, there are no robust and easily accessible biomarkers for the detection of sleepiness, even though the vast damage on society is well known. Thus, our findings will be of high value for many related disciplines. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT05585515, released on 18.10.2022; Swiss National Clinical Trial Portal SNCTP000005089, registered on 12 August 2022.
引用
- Scholz M, Lakaemper S, Keller K, et al. Metabolomics-based Sleepiness Markers for Risk Prevention and Traffic Safety (ME-SMART): a monocentric, controlled, randomized, crossover trial. Trials. 2023. PMID: 36810100. doi:10.1186/s13063-023-07154-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。